Pancreatic Cancer Research

Clinical trialPhase 1Completed

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

A Phase I Trial of Ascorbic Acid and Gemcitabine for the Treatment of Metastatic Pancreatic Cancer

NCT01049880↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
December 2009
Expected end
March 2013
Enrollment
15 participants
Sites
1
Primary outcomes
Blood cell counts (neutropenia, thrombocytopenia) and serum chemistries (liver function tests, creatinine)
Sponsor
Other
Results posted
No
Last update
21 April 2017

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is designed to determine the maximum tolerated dose of vitamin C when given with a standard chemotherapy for people who have metastatic pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

This is a phase I, dose-escalating study of ascorbic acid (vitamin C) designed to determine the maximum tolerated dose of vitamin C or, if well tolerated, the dose required to obtain a desired ascorbic acid plasma concentration. Because this is a phase I study, prospective subjects should have advanced disease (i.e., metastasis) and have failed other curative therapies (or, are unable to receive curative therapies due to comorbidities or stage of disease).

Papers 1

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.